Sanara MedTech Inc. SMTI
Industrial Specialties · data as of November 13, 2026
Sanara MedTech Inc. (SMTI) is a healthcare company listed in the US with a market value of about $297M. In the twelve months to September 30, 2026 it had revenue of $112M and net income of -$3M, a net margin of -2.7%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 40.7, 5-year revenue growth of 46% a year, a 5-year average ROIC of -6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 83% below the current price.
About Sanara MedTech
Sanara MedTech is listed in the US and classified in industrial specialties. Revenue went from $3M in 2014 to $103M in 2025, growth of about 39.6% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 9% over three years (dilution for shareholders). It spends 5% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 5-year revenue growth above 8% a year
- Positive free cash flow
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $112M | $103M | $87M | $65M | $46M | $24M | $16M | $12M | $6M | $6M | $6M |
| Net income | -$3M | -$38M | -$10M | -$4M | -$8M | -$8M | -$4M | -$3M | -$600574 | $331309 | -$415747 |
| Free cash flow | $7M | $2M | -$229632 | -$4M | -$6M | -$5M | -$5M | -$2M | $268660 | -$183757 | $406216 |
| EPS (diluted) | $-0.28 | $-4.36 | $-1.14 | $-0.52 | $-1.00 | $-1.08 | $-0.76 | $-1.32 | $0.00 | $0.00 | $-0.01 |
| Net margin | -2.7% | -36.4% | -11.2% | -6.6% | -17.3% | -32.8% | -28.5% | -23.9% | -10.3% | 5.2% | -7.5% |
| ROIC | — | 10.7% | 1.4% | -5.9% | -17.0% | -18.8% | -60.0% | -30.0% | -67.6% | 7.3% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $35.00, 8% above the current price; targets range from $35.00 to $35.00; the consensus rating is “Hold”; expected EPS is $0.20 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Sanara MedTech stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 83% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Sanara MedTech pay a dividend?
Not currently.
Is Sanara MedTech a good stock to buy?
We do not give buy or sell advice. Sanara MedTech scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.